文献速递预防保健、筛查与疫苗妇女保健

基于初级HPV检测的宫颈筛查间隔延长:英格兰筛查试点观察性研究

Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data.
PubMed 文献 · BMJ · 2022-05-31

结果显示25-49岁女性HPV阴性后5年筛查间隔、50岁及以上更长间隔有证据支持;HPV阳性但早期召回时HPV转阴者应维持3年间隔。

要点

  • 25-49岁女性HPV阴性后5年筛查间隔有数据支持
  • 50岁及以上女性HPV阴性后筛查间隔可更长
  • HPV阳性者早期召回时HPV阴性应维持3年间隔

核心结论

  • 数据支持延长筛查间隔:25-49岁女性HPV阴性后5年,50岁及以上女性可更长。
  • HPV阳性女性若在早期召回时HPV检测阴性,筛查间隔应保持3年。

研究设计与样本

  • 观察性研究,基于英格兰HPV筛查试点第一轮和第二轮真实世界数据(2013-16年,随访至2019年底)。

主要发现

  • 50岁以下女性第一轮HPV阴性后第二轮CIN3+检出为1.21/1000,细胞学筛查为4.52/1000(调整OR 0.26,95%CI 0.23-0.30)。
  • 50岁以上女性HPV阴性后5年第二轮CIN3+检出为0.57/1000,50岁以下女性3年为1.21/1000(调整OR 0.46,95%CI 0.27-0.79)。
  • HPV阳性但早期召回时HPV阴性者第二轮CIN3+检出为5.39/1000,初筛HPV阴性者为1.21/1000(调整OR 3.27,95%CI 2.21-4.84)。
  • APTTIMA mRNA HPV检测阴性后CIN3+检出与cobas和RealTime DNA检测相似(1.32/1000 vs 1.14/1000,调整OR 1.05,95%CI 0.73-1.50)。

关键数值与推荐

  • 25-49岁女性HPV检测阴性后筛查间隔可延长至5年。
  • 50岁及以上女性HPV检测阴性后筛查间隔可延长至超过5年。
  • HPV阳性女性在早期召回时HPV检测阴性者,筛查间隔应保持3年。
  • 筛查间隔延长建议不受所用HPV检测方法影响。

临床怎么用

  • 全科医生可依据年龄和HPV检测结果向患者解释延长宫颈筛查间隔的依据。
  • 对HPV阳性但早期召回转阴的女性,应提醒其按3年间隔继续筛查。
  • 不同HPV检测方法(APTTIMA mRNA、cobas、RealTime DNA)阴性后风险相似,可同等对待。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To provide updated evidence about the risk of cervical intraepithelial neoplasia grade 3 or higher (CIN3+) and cervical cancer after a negative human papillomavirus (HPV) test in primary cervical screening, by age group and test assay. DESIGN: Observational study. SETTING: Real world data from the English HPV screening pilot's first and second rounds (2013-16, follow-up to end of 2019). PARTICIPANTS: 1 341 584 women. INTERVENTIONS: Cervical screening with HPV testing or liquid based cytological testing (cytology or smear tests). Women screened with cytology were referred to colposcopy after high grade cytological abnormalities or after borderline or low grade abnormalities combined with a positive HPV triage test. Women screened with HPV testing who were positive were referred at baseline if their cytology triage test showed at least borderline abnormalities or after a retest (early recall) at 12 and 24 months if they had persistent abnormalities. MAIN OUTCOME MEASURES: Detection of CIN3+ and cervical cancer after a negative HPV test. RESULTS: For women younger than 50 years, second round detection of CIN3+ in this study was significantly lower after a negative HPV screen in the first round than after cytology testing (1.21/1000 v 4.52/1000 women screened, adjusted odds ratio 0.26, 95% confidence interval 0.23 to 0.30), as was the risk of interval cervical cancer (1.31/100 000 v 2.90/100 000 woman years, adjusted hazard ratio 0.44, 0.23 to 0.84). Risk of an incident CIN3+ detected at the second screening round in the pilot five years after a negative HPV test was even lower in women older than 50 years, than in three years in women younger than 50 years (0.57/1000 v 1.21/1000 women screened, adjusted odds ratio 0.46, 0.27 to 0.79). Women with negative HPV tests at early recall after a positive HPV screening test without cytological abnormalities had a higher detection rate of CIN3+ at the second routine recall than women who initially tested HPV negative (5.39/1000 v 1.21/1000 women screened, adjusted odds ratio 3.27, 95% confidence interval 2.21 to 4.84). Detection after a negative result on a clinically validated APTIMA mRNA HPV test was similar to that after clinically validated cobas and RealTime DNA tests (for CIN3+ at the second round 1.32/1000 v 1.14/1000 women screened, adjusted odds ratio 1.05, 0.73 to 1.50). CONCLUSIONS: These data support an extension of the screening intervals, regardless of the test assay used: to five years after a negative HPV test in women aged 25-49 years, and even longer for women aged 50 years and older. The screening interval for HPV positive women who have negative HPV tests at early recall should be kept at three years.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Rebolj M, Cuschieri K, Mathews CS, et al. Extension of cervical screening intervals with primary human papillomavirus testing: observational study of English screening pilot data. BMJ. 2022. PMID: 35640960. doi:10.1136/bmj-2021-068776

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。